Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Impedimed Limited ( (AU:IPD) ).
ImpediMed Limited announced that a major US health insurer has issued positive coverage for bioimpedance spectroscopy (BIS) under CPT Code 93702, recognizing it as medically necessary for lymphedema assessment. This development significantly expands insurance coverage for ImpediMed’s SOZO® Digital Health Platform, now covering over 301 million lives and 86% of the US population. The decision is expected to enhance the commercial viability of SOZO, allowing for earlier detection and better management of lymphedema, thus improving the quality of life for breast cancer survivors. This expanded coverage is a crucial step towards proactive health management and aligns with the insurer’s mission to provide high-quality care.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.14 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited is a medical technology company headquartered in Brisbane, Australia, with operations in the US and Europe. The company specializes in bioimpedance spectroscopy (BIS) technology to generate data for patient health optimization. Its flagship product, the SOZO® Digital Health Platform, is FDA-cleared, CE-marked, and ARTG-listed for various medical conditions, including lymphedema, heart failure, and protein calorie malnutrition. ImpediMed operates on a SaaS subscription-based model, targeting the cancer-related lymphedema market.
Average Trading Volume: 2,084,865
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$69.23M
For detailed information about IPD stock, go to TipRanks’ Stock Analysis page.